Cargando…
The effect of the response to the coronavirus disease pandemic on treatment outcomes in patients with lymphoma and multiple myeloma
BACKGROUND/AIMS: Relatively little data are available on how the response to the coronavirus disease 2019 (COVID-19) pandemic has affected treatment outcomes in patients receiving chemotherapy for lymphoma or multiple myeloma. We aimed to determine the effect of COVID-19 countermeasures on treatment...
Autores principales: | Kang, Ka-Won, Lee, Byung-Hyun, Jeon, Min Ji, Yu, Eun Sang, Kim, Dae Sik, Lee, Se Ryeon, Sung, Hwa Jung, Choi, Chul Won, Park, Yong, Kim, Byung Soo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Association of Internal Medicine
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8588990/ https://www.ncbi.nlm.nih.gov/pubmed/34666434 http://dx.doi.org/10.3904/kjim.2021.186 |
Ejemplares similares
-
Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma
por: Kim, Dae Sik, et al.
Publicado: (2017) -
Prediction Model for Cereblon Expression in Bone Marrow Plasma Cells Based on Blood Markers in Multiple Myeloma Patients
por: Lee, Byung-Hyun, et al.
Publicado: (2021) -
Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
por: Lee, Se Ryeon, et al.
Publicado: (2019) -
PVR (CD155) Expression as a Potential Prognostic Marker in Multiple Myeloma
por: Lee, Byung-Hyun, et al.
Publicado: (2022) -
Lack of usefulness of computed tomography for surveillance in patients with aggressive non-Hodgkin lymphoma
por: Kang, Ka-Won, et al.
Publicado: (2018)